Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda
Posted:
Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data show early hints of the medicine improving patient survival — the gold standard outcome of any cancer study.
Sonographers conduct ultrasound scans which are essential to pregnancy care and are also used in the diagnosis of cancer.
Pregnant women are offered a scan when their baby is 12 weeks old and again when the baby is 20 weeks.…
Almost 1,000 participants have been recruited into a liver disease study in less than a year using real-world NHS data. It uses software to identify and stratify individuals using historic blood test data held in NHS systems.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us